Solriamfetol Titration and AdministRaTion (START) in Patients with Obstructive Sleep Apnea: A Retrospective Chart Review and Hypothetical Patient Scenario

Introduction Solriamfetol (Sunosi™), a dopamine/norepinephrine reuptake inhibitor, is approved (USA and EU) to treat excessive daytime sleepiness (EDS) in adults with obstructive sleep apnea (OSA) (37.5–150 mg/day). Real-world research on solriamfetol initiation is limited. The objective of this stu...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Advances in therapy 2022-09, Vol.39 (9), p.4359-4373
Hauptverfasser:	Singh, Haramandeep, Hyman, Danielle, Parks, Gregory S., Chen, Abby, Foley, Catherine, Baldys, Beth, Ito, Diane, Thorpy, Michael J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Cardiology Endocrinology Internal Medicine Medicine Medicine & Public Health Oncology Original Research Pharmacology/Toxicology Rheumatology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!